News >

Liquid Biopsies: Complementary Tool in Detecting Driver Mutations in NSCLC

Caroline Seymour
Published: Wednesday, May 22, 2019

Dr. Sai-Hong Ignatius Ou

Sai-Hong Ignatius Ou, MD, PhD

Liquid biopsies can be used to augment tissue biopsies in non–small cell lung cancer (NSCLC), and in the case of insufficient tumor tissue, serve as the primary method of detecting a potentially actionable driver mutation with a faster turnaround time, explained Sai-Hong I. Ou, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication